These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22802247)

  • 1. The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model.
    Deris ZZ; Yu HH; Davis K; Soon RL; Jacob J; Ku CK; Poudyal A; Bergen PJ; Tsuji BT; Bulitta JB; Forrest A; Paterson DL; Velkov T; Li J; Nation RL
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5103-12. PubMed ID: 22802247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.
    Bergen PJ; Tsuji BT; Bulitta JB; Forrest A; Jacob J; Sidjabat HE; Paterson DL; Nation RL; Li J
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5685-95. PubMed ID: 21911563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model.
    Lee HJ; Bergen PJ; Bulitta JB; Tsuji B; Forrest A; Nation RL; Li J
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3738-45. PubMed ID: 23716052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula.
    Bergen PJ; Forrest A; Bulitta JB; Tsuji BT; Sidjabat HE; Paterson DL; Li J; Nation RL
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5134-42. PubMed ID: 21876058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of porin expression in Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems.
    Hong JH; Clancy CJ; Cheng S; Shields RK; Chen L; Doi Y; Zhao Y; Perlin DS; Kreiswirth BN; Nguyen MH
    Antimicrob Agents Chemother; 2013 May; 57(5):2147-53. PubMed ID: 23459476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model.
    Lora-Tamayo J; Murillo O; Bergen PJ; Nation RL; Poudyal A; Luo X; Yu HY; Ariza J; Li J
    J Antimicrob Chemother; 2014 Sep; 69(9):2434-42. PubMed ID: 24833752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae.
    Jernigan MG; Press EG; Nguyen MH; Clancy CJ; Shields RK
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3395-8. PubMed ID: 22430958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance.
    Ly NS; Bulitta JB; Rao GG; Landersdorfer CB; Holden PN; Forrest A; Bergen PJ; Nation RL; Li J; Tsuji BT
    J Antimicrob Chemother; 2015 May; 70(5):1434-42. PubMed ID: 25712313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic Activity of Colistin/Fosfomycin Combination against Carbapenemase-Producing
    Wang J; He JT; Bai Y; Wang R; Cai Y
    Biomed Res Int; 2018; 2018():5720417. PubMed ID: 29850537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microbiological efficiency of the combinations of two carbapenems against antibiotic resistant Klebsiella pneumoniae strains.
    Tapalski DV; Timoshkova EV; Petrovskaya TA; Osipkina OV; Karpov IA
    Klin Lab Diagn; 2021 May; 66(5):304-309. PubMed ID: 34047517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii.
    Park GC; Choi JA; Jang SJ; Jeong SH; Kim CM; Choi IS; Kang SH; Park G; Moon DS
    Ann Lab Med; 2016 Mar; 36(2):124-30. PubMed ID: 26709259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae.
    Tascini C; Tagliaferri E; Giani T; Leonildi A; Flammini S; Casini B; Lewis R; Ferranti S; Rossolini GM; Menichetti F
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3990-3. PubMed ID: 23752510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doripenem, gentamicin, and colistin, alone and in combinations, against gentamicin-susceptible, KPC-producing Klebsiella pneumoniae strains with various ompK36 genotypes.
    Clancy CJ; Hao B; Shields RK; Chen L; Perlin DS; Kreiswirth BN; Nguyen MH
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3521-5. PubMed ID: 24566172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin.
    Clancy CJ; Chen L; Hong JH; Cheng S; Hao B; Shields RK; Farrell AN; Doi Y; Zhao Y; Perlin DS; Kreiswirth BN; Nguyen MH
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5258-65. PubMed ID: 23939888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae.
    Poudyal A; Howden BP; Bell JM; Gao W; Owen RJ; Turnidge JD; Nation RL; Li J
    J Antimicrob Chemother; 2008 Dec; 62(6):1311-8. PubMed ID: 18922815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an
    Bian X; Liu X; Chen Y; Chen D; Li J; Zhang J
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.
    Yadav R; Bulitta JB; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of the Novel Aminoglycoside Acetyltransferase Variant
    Sato T; Wada T; Nishijima S; Fukushima Y; Nakajima C; Suzuki Y; Takahashi S; Yokota SI
    mBio; 2020 Dec; 11(6):. PubMed ID: 33443109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates.
    Vidaillac C; Benichou L; Duval RE
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4856-61. PubMed ID: 22751540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies.
    Rao GG; Ly NS; Bulitta JB; Soon RL; San Roman MD; Holden PN; Landersdorfer CB; Nation RL; Li J; Forrest A; Tsuji BT
    J Antimicrob Chemother; 2016 Nov; 71(11):3148-3156. PubMed ID: 27494922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.